| Source: |
| Type: white blood cell |
| T cells are white blood cells that play a central role in the adaptive immune response. Subsets and Function: Cytotoxic T Cells (CD8+): Recognize and kill infected or malignant cells. Helper T Cells (CD4+): Assist in orchestrating the immune response by secreting cytokines and supporting the functions of other immune cells. T cells, particularly CD8+ cytotoxic T cells, can recognize tumor antigens presented on major histocompatibility complex (MHC) molecules and directly kill malignant cells. Regulatory T Cells (Tregs): Maintain immune tolerance and prevent autoimmunity but may also suppress anti-tumor responses in the tumor microenvironment. Tumor-Infiltrating Lymphocytes (TILs): Tumor Microenvironment: The presence of T cells within tumors, often referred to as tumor-infiltrating lymphocytes, is a key indicator of an ongoing anti-tumor immune response. Regulatory T Cells (Tregs): Tregs within the tumor environment may inhibit the activity of cytotoxic T cells through the secretion of immunosuppressive cytokines (e.g., IL-10, TGF-β), thus allowing tumors to evade the immune response. In many cancers, a robust T cell infiltrate is correlated with a better overall survival, lower rates of relapse, and improved responses to therapy. Assessing the type, density, and activation state of T cells in the tumor microenvironment can provide valuable prognostic information. High levels of active, cytotoxic T cells generally indicate a better prognosis. |
| 1024- | Api, | CUR, | Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects |
| - | vitro+vivo, | Melanoma, | A375 | - | in-vitro, | Melanoma, | A2058 | - | in-vitro, | Melanoma, | RPMI-7951 |
| 1029- | Ba, | BA, | Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells |
| - | vitro+vivo, | HCC, | NA |
| 1244- | CGA, | immuno, | Cancer Differentiation Inducer Chlorogenic Acid Suppresses PD-L1 Expression and Boosts Antitumor Immunity of PD-1 Antibody |
| - | in-vivo, | NA, | NA |
| 1574- | Citrate, | Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Melanoma, | WM983B | - | in-vivo, | NA, | NA |
| 1034- | CUR, | immuno, | Enhanced anti‐tumor effects of the PD‐1 blockade combined with a highly absorptive form of curcumin targeting STAT3 |
| - | in-vivo, | NA, | NA |
| 451- | CUR, | The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer |
| - | vitro+vivo, | HNSCC, | SCC15 | - | vitro+vivo, | HNSCC, | SNU1076 | - | vitro+vivo, | HNSCC, | SNU1041 |
| 1038- | Fuc, | immuno, | Fucoidan enhances the anti-tumor effect of anti-PD-1 immunotherapy by regulating gut microbiota. |
| - | in-vivo, | BC, | NA |
| 1021- | HNK, | Honokiol suppress the PD-L1 expression to improve anti-tumor immunity in lung cancer |
| - | in-vivo, | Lung, | NA |
| 7653- | IP, | Generation of systemic antitumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel |
| - | in-vivo, | Var, | NA |
| 8237- | LCA, | Role of Licochalcone A in Potential Pharmacological Therapy: A Review |
| - | Review, | Var, | NA |
| 8212- | LCA, | Licochalcone A inhibits proliferation and promotes apoptosis of colon cancer cell by targeting programmed cell death-ligand 1 via the NF-κB and Ras/Raf/MEK pathways |
| - | in-vitro, | Colon, | HepG3 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Cerv, | HeLa | - | vitro+vivo, | CRC, | HCT116 |
| 8129- | LF, | Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy |
| - | Trial, | CRC, | NA |
| 1782- | MEL, | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities |
| - | Review, | Var, | NA |
| 220- | MFrot, | MF, | Effect of low frequency magnetic fields on melanoma: tumor inhibition and immune modulation |
| - | in-vitro, | Melanoma, | B16-F10 |
| 1573- | MushReishi, | Ganoderma lucidum (Reishi mushroom) for cancer treatment |
| - | Review, | NA, | NA |
| 3- | MushShi, | AHCC Activation and Selection of Human Lymphocytes via Genotypic and Phenotypic Changes to an Adherent Cell Type: A Possible Novel Mechanism of T Cell Activation |
| 103- | RES, | CUR, | QC, | The effect of resveratrol, curcumin and quercetin combination on immuno-suppression of tumor microenvironment for breast tumor-bearing mice |
| - | vitro+vivo, | BC, | 4T1 |
| 871- | RES, | CUR, | QC, | The effect of resveratrol, curcumin and quercetin combination on immuno-suppression of tumor microenvironment for breast tumor-bearing mice |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | BC, | 4T1 |
| 1195- | SM, | Salvia miltiorrhiza polysaccharide activates T Lymphocytes of cancer patients through activation of TLRs mediated -MAPK and -NF-κB signaling pathways |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | CRC, | HCT116 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:1 prod#:% Target#:300 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid